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Factors that influence clinicians’ decisions
to offer intravenous alteplase in acute
ischemic stroke patients with uncertain
treatment indication: Results of a
discrete choice experiment
Aoife De Bru´n1, Darren Flynn1, Laura Ternent1,
Christopher I Price2,3, Helen Rodgers3, Gary A Ford4,
Matthew Rudd2, Emily Lancsar5, Stephen Simpson6, John Teah6
and Richard G Thomson1
Abstract
Background: Treatment with intravenous alteplase for eligible patients with acute ischemic stroke is underused, with
variation in treatment rates across the UK. This study sought to elucidate factors influencing variation in clinicians’
decision-making about this thrombolytic treatment.
Methods: A discrete choice experiment using hypothetical patient vignettes framed around areas of clinical uncertainty
was conducted with UK-based clinicians. Mixed logit regression analyses were conducted on the data.
Results: A total of 138 clinicians completed the discrete choice experiment. Seven patient factors were individually
predictive of increased likelihood of immediately offering IV alteplase (compared to reference levels in brackets): stroke
onset time 2 h 30min [50 min]; pre-stroke dependency mRS 3 [mRS 4]; systolic blood pressure 185mm/Hg [140 mm/
Hg]; stroke severity scores of NIHSS 5 without aphasia, NIHSS 14 and NIHSS 23 [NIHSS 2 without aphasia]; age 85 [68];
Afro-Caribbean [white]. Factors predictive of withholding treatment with IV alteplase were: age 95 [68]; stroke onset
time of 4 h 15min [50 min]; severe dementia [no memory problems]; SBP 200mm/Hg [140 mm/Hg]. Three clinician-
related factors were predictive of an increased likelihood of offering IV alteplase (perceived robustness of the evidence
for IV alteplase; thrombolyzing more patients in the past 12 months; and high discomfort with uncertainty) and one with
a decreased likelihood (high clinician comfort with treating patients outside the licensing criteria).
Conclusions: Both patient- and clinician-related factors have a major influence on the use of alteplase to treat patients
with acute ischemic stroke. Clinicians’ views of the evidence, comfort with uncertainty and treating patients outside the
license criteria are important factors to address in programs that seek to reduce variation in care quality regarding
treatment with IV alteplase. Further research is needed to further understand the differences in clinical decision-making
about treating patients with acute ischemic stroke with IV alteplase.
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Introduction
Stroke remains a leading cause of death and disability.1
Thrombolysis with recombinant tissue plasminogen
activator (intravenous (IV) alteplase) is a cost-effective
treatment for acute ischemic stroke that reduces stroke-
related disability, but unwarranted variation exists in
UK thrombolysis rates2 despite a strong evidence
base3,4 reflected in the National Stroke Strategy,5
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National Institute for Health and Care Excellence
(NICE) guidelines,6 and treatment licensing criteria.7
Since the expansion of 24/7 hyper-acute stroke services,
organizational factors seem less likely to explain this
variation, which may be accounted for by variation in
clinical decision-making, based on interpretation and
understanding of clinical factors, and on characteristics
of the individual decision-makers (such as experience,
attitude towards risk). The study aimed to elucidate
patient and clinician factors that influence clinicians’
decision-making about the offer of IV alteplase to
patients with acute ischemic stroke.
Clinical decision-making about IV alteplase is com-
plex. The time limited window for treatment (maximum
4.5 h since symptom onset) and the many clinical factors
that might influence the balance between the risk and
benefit for individual patients factor into this high stakes
decision.8 Earlier treatment is associated with better out-
comes, yet there is a small but significant risk of adverse
outcomes, mainly due to treatment-related symptomatic
intracranial hemorrhage (sICH).9Decision-making is fur-
ther complicated by uncertainty in research evidence, typ-
ically where high-quality data from randomized
controlled trials do not exist regarding the suitability of
certain patients for treatment with IV alteplase.10
In order to understand the variation in treatment
rates,2 the lack of expert consensus on several treatment
exclusion criteria,11 and on-going debates regarding the
efficacy of IV alteplase,12,13 a research method is
required that reflects decision-making in practice.14 A
discrete choice experiment (DCE) facilitates the inves-
tigation of multiple factors in a decision and is there-
fore appropriate for exploring this complex decision.
This method enables the nuances of decision-making
to be understood by providing insights not easily cap-
tured using more traditional research methods, such as
interviews or observation. DCEs have been increasingly
adopted to examine healthcare decision-making,
including stroke rehabilitation.15 Through a novel
DCE approach, this study aimed to elucidate the fac-
tors influencing and contributing to variation in clin-
icians’ decision-making about treating patients with
acute ischemic stroke with IV alteplase, with a focus
on areas of clinical uncertainty and borderline cases.
Methods
Study design
The DCE development process consisted of five itera-
tive stages, informed by current good practice recom-
mendations.16–18 Through expert design and pilot
testing,19 hypothetical patient vignettes mimicked the
clinical decision and required a binary response (offer
IV alteplase or not). Supplementary Tables 1 and 2
describe factors and levels included in the study and
their accompanying definitions. Optional free text
boxes were included after each vignette for participants
to comment on their decision-making, assisting with
interpretation of findings (further design information
and qualitative results methods can be found online
as Supplementary material). A blocked design allowed
a subset of vignettes to be presented to each participant
to avoid overburdening participants (Figure 1).
An online survey also included questions and
measurement scales to collect information on clinician
characteristics that were hypothesized to influence
decision-making, including demography and level of
experience. A scale was developed to gauge the institu-
tional culture with respect to thrombolysis
(‘‘Institutional Culture Scale,’’ see Supplementary
Table 3). The risk-taking sub-scale of the Jackson
Personality Inventory (JPI)20 and the Physician
Reaction to Uncertainty Scale21 were also employed.
Clinicians were asked to state how recent their last
thrombolysis decision was, and howmany stroke patients
they had treated with IV alteplase and how many were
harmed as a result, in the past 12months. Six-point Likert
scales were used to assess the impact of clinicians’ level of
comfort treating a patient outside the licensing criteria
and their views on the strength of the evidence base.
Ethical approval was obtained from Newcastle
University Research Ethics Committee (reference:
00720/2013).
Recruitment
UK clinicians who were involved in decision-making
regarding the offer of IV alteplase for patients with
acute ischemic stroke were recruited via newsletters
and emails sent through relevant professional associ-
ations, including the British Association of Stroke
Physicians, Society for Acute Medicine, College of
Emergency Medicine, British Geriatrics Society, and
Association of British Neurologists. An invitation to
participate was also sent to UK Safe Implementation
of Treatments in Stroke (SITS) coordinators and infor-
mation about the study was included on the Sentinel
Stroke National Audit Programme (SSNAP) website.
A screening question was first provided to participants
ensuring they were involved in the ‘‘final decision-
making’’ about thrombolysis. The survey was live for
six months from September 2014.
Statistical analysis
Data were analyzed in STATA IC13.22 Mixed logit
regression (mixlogit) analyses were conducted to facili-
tate the examination of heterogeneity amongst
respondents. The intercept (alternative specific
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constant; ASC) and model parameters were assumed to
be random and normally distributed. A positive coeffi-
cient for a level of a factor in the mixlogit models,
compared with the reference level of the factor, repre-
sents a driver of a decision to offer treatment with IV
alteplase, whereas a negative coefficient represents an
inhibiting influence on decisions to offer this treatment
(i.e. more likely not to offer treatment). Significance was
set at a P-value of <0.05, and the odds ratios (95%
confidence intervals) were calculated to show magni-
tude/precision of effects in the regression models:
patient-related factors (model 1) and both patient and
clinician-related factors (model 2). Implausible combin-
ations (e.g. pre-stroke dependency of mRS 1 and severe
dementia) were omitted from the regression models. In
addition, to control for the effects of block design, seven
dummy variables were included in the analyses (com-
paring each design block to block 1).
Results
Sample characteristics
Table 1 presents a summary of the socio-demographic
profile and other characteristics of respondents
(N¼ 138). Respondents had a mean age of 46 years
(range: 30–68). The majority were male (73%) and
stroke physicians (59%). The average experience treat-
ing stroke patients and administering intravenous alte-
plase was 11 years (range: 3 months–38 years) and 6
years 4 months (range: 3 months–22 years), respect-
ively. Although no information is available about the
non-respondents to the online survey, the profile of
the respondents is broadly representative of the popu-
lation of medical professionals involved in acute
stroke care in the UK. Based on data from the
SSNAP acute organisation audit,23 the profile of the
current sample in terms of medical specialty is pro-
portionately representative of those involved in deci-
sion-making about treatment of acute stroke patients;
stroke physicians are most often on thrombolysis
rotas, followed in decreasing order by geriatricians,
neurologists, accident and emergency (A&E) and
acute medicine physicians. Furthermore, the average
age and gender distribution in the current sample is
consistent with data from the Royal College of
Physicians (RCP) 2012 census.24
Reliability analyses were conducted on the scales
employed in the survey and showed good to high reli-
ability across scales (Supplementary material).
Figure 1. Sample patient vignette.
A 95 year old Asian man has been admitted to hospital with acute ischaemic 
stroke. Symptom onset began 4 hours 15 minutes ago. The patient, who you 
perceive as frail, had a pre-stroke dependency mRS of 3. Further investigation 
revealed the patient is not on anticoagulation therapy and has a blood glucose 
level of 6 mmol/L. The patient has no history of memory problems and at the time 
of treatment decision, the patient’s systolic blood pressure is 185mm/Hg. The 
patient has no recent history of significant bleeding and no history of diabetes. 
Clinical assessment of stroke severity indicated a NIHSS score of 5 (with 
aphasia). A CT scan was conducted and is consistent with ischaemic stroke; it 
shows no haemorrhage or new ischaemic changes. There are no other factors 
which would deter treatment. 
Given the information presented above, would you immediately offer 
thrombolysis to this patient? 
Yes  
No 
Do you have any comments about this case? 
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Table 1. Characteristics of sample (N¼ 138)
Variables
Mean (SD) N (%)
Age 46 (8.7)
Male 101 (73)
Medical specialty
Stroke medicine 81 (59)
Accident & Emergency 20 (15)
Geriatric medicine 17 (12)
Neurology 17 (12)
Acute care 3 (2)
Grade/seniority
Consultant 123 (89)
Staff doctor 6 (4)
Speciality trainee 7 (5)
Other 2 (2)
Experience with treating acute ischemic stroke (months) 132 (99)
Experience with administering IV alteplase (months) 76 (43)
Willing to control blood pressure (where applicable)
before treatment with IV alteplase
132 (96)
Formal protocol is available for assessing patient eligibility for
treatment with IV alteplase
136 (99)
Number of clinicians who report that there are occasions when they
do not strictly adhere to the protocol for assessing patient
eligibility for treatment with IV alteplase
93 (67)
Service configuration
Consultant-led 61 (44)
Combined telemedicine and consultant-led 77 (56)
Risk-taking scale score 219 (5.33)
Physicians’ reaction to uncertainty scale score 1286 (9.39)
Institutional culture scale score 2473 (5.24)
Perception of the evidence base for treatment with IV alteplase 467 (1.36)
Confidence communicating benefits/risks of
treatment with IV alteplase
512 (1.02)
Number of days since last IV alteplase decision made 18 (38)
(continued)
International Journal of Stroke, 0(0)
4 International Journal of Stroke 0(0)
There was overall general preference not to offer
IV alteplase to patients described in the hypothetical
vignettes, with 1103 decisions (68.6%) not to offer
treatment with IV alteplase compared to 504 decisions
to offer the treatment (31.4%).
DCE regression results
Model 1 – Patient-related factors (Supplementary
Table 4). Compared to their reference categories (in
brackets), four patient factors were statistically sig-
nificant predictors of decisions not to offer treatment
with IV alteplase: patient age of 95 [68]; time since
stroke symptom onset 4 h 15min [50 min]; patients
with severe dementia [no history of memory problems];
and systolic blood pressure (SBP) of 200mm/Hg
[140 mm/Hg].
There were eight statistically significant predictors of
decisions to offer (compared to reference levels in
brackets): patient age of 85 years [68]; Afro-
Caribbean ethnicity [white]; time since stroke symptom
onset of 2 h 30min [50 min]; pre-stroke dependency
score of mRS 3 [mRS 4]; and SBP of 185mm/Hg [140
mm/Hg]. Compared with the stroke severity reference
category of the National Institutes of Health Stroke
Scale25 (NIHSS) score of 2 without aphasia, respond-
ents were significantly more likely to offer thrombolysis
to patients with scores of NIHSS 5 without aphasia,
NIHSS 14 and NIHSS 23.
The standard deviation for the ASC was statistic-
ally significant suggesting considerable heterogeneity
among respondents in decision-making. There was
also substantial heterogeneity on several of the
random effects coefficients, with nine standard devi-
ations significant, indicating the variation between
participants in their IV alteplase decisions as a func-
tion of differing levels of patient-related factors.
Model 2 – Patient-related and clinician factors (Supplementary
Table 5). Model 2 added seven clinician characteristics
to the patient-related factors: respondents’ perception
of the effectiveness and safety of treating acute ischemic
stroke patients with IV alteplase; physician reaction to
uncertainty scale; clinicians’ attitude towards risk; esti-
mated number of patients harmed by IV alteplase in the
past 12 months and days since a patient was harmed;
estimated number of patients treated with IV alteplase
in the past 12 months; and comfort treating patients
outside licensing criteria.
The standard deviation for the ASC for Model 2 was
also statistically significant, which indicates the pres-
ence of considerable heterogeneity among respondents
regarding their decisions about treating patients
with IV alteplase. There was considerable heterogeneity
for the random effects coefficients (i.e. the levels of
patient factors), with the standard deviations of 17
factor levels emerging as statistically significant. All
the statistically significant patient factor predictors
from Model 1 remained significant in Model 2, but
two additional patient factors became statistically sig-
nificant predictors of decisions to offer treatment with
IV alteplase: moderate dementia; and NIHSS 5 with
aphasia.
Respondents’ were significantly more likely to offer
treatment of IV alteplase when they perceived the evi-
dence base for this treatment to be robust; had treated a
high number of patients in the past 12 months; and
reported a higher level of discomfort with uncertainty.
Clinicians who reported being comfortable treating
patients outside the licensing criteria were significantly
less likely to offer thrombolysis.
Comparison of the Akaike and Bayesian informa-
tion criteria established that Model 2 was a better fit
for these data than Model 1.
The predicted probabilities of offering IV alteplase
for patients with acute ischemic stroke based on Model
1 are presented in Supplementary Table 6.
Discussion
This is the first DCE to explore patient and clinician
factors that influence the decision to offer IV alteplase
(thrombolysis) to treat patients with acute ischemic
stroke, with a particular focus on areas of uncertainty
and borderline cases. For the vignettes included in this
study, analysis revealed an aggregate level preference
Table 1. Continued
Variables
Mean (SD) N (%)
Number of patients treated with IV alteplase
by respondents in last 12 months
19 (15)
Number of patients harmed as a result of treatment with IV alteplase in last 12 months 08 (1.05)
Days since patient was harmed as a result of treatment with IV alteplase 408 (744)
International Journal of Stroke, 0(0)
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not to offer this treatment, which was expected given
that the vignettes were designed to explore decisions
related to the ‘‘gray’’ areas of the licensing and evidence
base for treatment.
Levels of seven different patient-related factors
(patient age, patient ethnicity, stroke symptom onset
time, pre-stroke dependency, systolic blood pressure,
stroke severity [NIHSS]25; and pre-stroke cognitive
status) and four different clinician-related ‘‘psycho-
social’’ factors (perception of the evidence for the
effectiveness and safety of IV alteplase, number of
patients treated in the past 12 months, comfort with
uncertainty, and comfort with treating patients outside
the licensing criteria) were significant predictors of the
treatment decision.
Patients aged 95 were significantly less likely to be
offered treatment compared with patients aged 68.
However, respondents were significantly more likely
to treat 85 year olds compared with patients aged 68.
The benefits of thrombolysis for older patients in terms
of reduction in disability are at least as great as
younger patients, despite an increased risk of symp-
tomatic intracranial hemorrhage. This may also reflect
the acceptance of a high profile clinical trial and case–
control study data that reports benefit for patients aged
>80, in particular for those with onset to treatment
time of <3 h.3,4 It is feasible that a social desirability
effect explains this latter finding; respondents may be
over-compensating (pro-actively recommending a posi-
tive decision) to avoid denying treatment based on age.
It appears that clinicians are not disinclined to treat
older patients, but less likely to treat the very old
(95). This may reflect the upper limit of data from
IST-3 or clinical experience (there are few patients who
have been treated in this age range in routine practice).
SITS data indicate that only approximately 10% of
treated patients were older than 8026 and national
audit data suggest that only 2.5% of the total
number of patients who received IV alteplase between
April 2010 and November 2011 were older than
90 years.27
Consistent with evidence of increased benefit with
earlier treatment,4 we identified a statistically signifi-
cant decreased likelihood of offering treatment to
patients who could be treated at 4 h 15min compared
to 50min from symptom onset. However, clinicians
were significantly more likely to treat patients at 2 h
30min relative to 50min. This unexpected finding sug-
gests that some clinicians rarely see patients this soon
after onset or that clinicians might observe cases pre-
senting early for a short while, particularly if there are
factors which create high uncertainty; for instance in
mild stroke, when a patient’s symptoms are rapidly
improving, to see if symptoms may resolve (per licen-
sing guidelines7), or to give blood pressure time to
stabilize or to take more readings before making a
final decision.28,29 This is in contrast to research
which confirms that earlier treatment is associated
with substantially more favorable outcomes,9 particu-
larly when treatment occurs within the ‘‘golden hour’’
(<60min from symptom onset).29
Respondents were significantly more likely to offer
IV alteplase to patients with moderate or severe stroke
and not offer IV alteplase to patients with mild stroke.
These findings are likely to reflect the lack of data and/
or uncertainty around the risk/benefit ratio of treat-
ment of minor stroke and the otherwise poor outcomes
for untreated patients with severe strokes. There was
significant heterogeneity among respondents on the
influence of NIHSS 2 with aphasia and NIHSS 5 with-
out aphasia, implying that clinicians differ in their
thresholds for treatment of minor stroke and may con-
sider the gains in quality of life for individual patients
with isolated language deficits differently.
Compared to white patients, Afro-Caribbean
patients were significantly more likely to be offered
treatment, though there was no effect for Asian ethni-
city. The explanation for this finding is unclear.
Patients with pre-stroke dependency of mRS 3 were
more likely to be offered treatment than those with
mRS 4. We would have expected that respondents
would be more willing to treat patients with mRS 1
compared to mRS 4, but this did not emerge.
However, the failure of this to reach significance may
be due to an imbalance between the levels of pre-stroke
dependency across vignettes in the study, where mRS 1
vignettes were significantly underrepresented.
Patients presenting with severe dementia were sig-
nificantly less likely to be offered IV alteplase in
Models 1 and 2, although in Model 2, clinicians were
more likely to offer treatment to those with moderate
dementia (compared to patients with no memory prob-
lems). This is difficult to explain but may be due to an
attempt to preserve a patients’ independence when
there is already a low probability that this might be
retained. Inspection of the standard deviations reveals
significant variation between respondents on the influ-
ence of both moderate and severe dementia on decision-
making. This may show that clinicians are weighing up
the pros and cons of treatment with reference to indi-
vidual patient characteristics that are not part of the
licensing criteria, although it may also reflect percep-
tions that dementia reduces likelihood of clinical benefit
or is associated with an increased risk of adverse effects.
However, current evidence suggests there is no
increased risk of adverse effects from IV alteplase in
patients with dementia.30
Four of the seven clinician factors emerged as sig-
nificant. There was a significant association found
between the respondents’ perception of the evidence
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base and the offer of treatment with IV alteplase.
Greater discomfort with uncertainty was associated
with increased likelihood of offering IV alteplase. This
may indicate a preference for action over inaction in
instances of high uncertainty, or what may be termed
commission bias when observed consistently.31
Commission bias is defined as the tendency towards
action/intervention rather than inaction.31 Given the
high scores observed on the Institutional Culture
Scale in the study (indicating a strong culture of admin-
istering IV alteplase to patients with acute ischemic
stroke in respondents’ institutions), clinicians may
worry more about decisions not to treat and, therefore,
those with higher levels of discomfort with uncertainty
may be more willing to provide this treatment, if it is
perceived as the dominant or favored position among
colleagues. The results also indicated that clinicians
who reported being more comfortable treating patients
outside the licensing criteria were less likely to offer
treatment in the current study; we do not have an
explanation for this finding.
Finally, there was a significant positive association
between clinicians’ experience of administering IV
alteplase and the likelihood of offering the treatment
in the current study. This may indicate that familiar-
ity with administration of the treatment (and positive
outcomes) increases the likelihood of future use and
has important practical implications for how clin-
icians are supported when they begin involvement
in decision-making.32 Alternatively, it may simply
represent that those more likely to offer treatment
in the DCE are more likely to offer treatment in
practice, and therefore have higher reported treat-
ment rates.
A key strength of this study was our ability to
account for both observed heterogeneity among
respondents (via inclusion of clinician factors in the
model) as well as unobserved variation (via the estima-
tion of random parameters for the alternative specific
constant and factor levels) using the mixed logit regres-
sion. Our research offers an important contribution
towards a deeper understanding of the factors influen-
cing the decision to offer IV alteplase to patients, in
particular factors that influence decisions for patients
who fall within the licensing criteria ‘‘gray’’ zone.
However, a limitation of the study was the potential
for response bias, given we cannot be certain about
the absolute number of eligible clinicians who received
the invitation to participate.
There were a number of results in this study that
were unexpected, for example, respondents were more
likely to offer IV alteplase to patients presenting with a
stroke onset time of 2 h 30min compared to 50min. We
do not have clear explanations for these findings with-
out undertaking additional data collection. There are at
least three issues to consider:
1. Technical: as a reflection of the degree of clinical
uncertainty being examined by the vignettes, the
responses did not contain enough positive responses
for some factor levels to fully explore interactions
between different factors/levels. A larger cohort or
number of vignettes would have enabled greater cer-
tainty about the dependency between different factor
levels and factors. A replication of the current study
using a broader range of factor levels (e.g. for pre-
stroke dependency) and including vignettes, where
there is likely to be clear consensus about whether
or not to offer IV alteplase would help to clarify the
results observed in this study.
2. Overcorrection: Respondents may have used their
responses to emphasize a particular point which
had been recently highlighted by clinical or research
developments (e.g. evidence to support treatment of
patients >80 years old), or to avoid a perception of
bias against certain demographic groups.
3. Diagnostic uncertainty: The decision to treat patients
with IV alteplase involves a high degree of confidence
that ischemic stroke is the cause of the acute symp-
toms. Despite assurance that only patients with acute
ischemic stroke were being described in the vignettes,
respondents may have been influenced by their clin-
ical experience with stroke mimics. For instance, this
may explain the apparent greater enthusiasm to treat
at 2 h 30min rather than 50min, as respondents may
have been concerned that the former could resolve
and be a transient ischemic attack (TIA) rather than
stroke. This may be a training issue which should be
addressed.
Training for the assessment and treatment of patients
with acute ischemic stroke should address the impact
of the influence of clinician factors on decision-
making, impart cognitive de-biasing strategies to opti-
mize and support decision-making, and should ensure
clinicians develop practical learning and self-efficacy in
the administration of IV alteplase to eligible patients
early in training to maximize appropriate treatment util-
ization. The use of patient vignettes as choice
scenarios which focus on the ‘‘gray’’ areas in decision-
making are useful in generating discussion and revealing
differences in individual-level clinical decision-making.
Future DCEs could feed back information to partici-
pants about their decision-making relative to other
experienced colleagues, and inform reflective practice
and professional development. High-quality clinical stu-
dies are also required to inform ‘‘gray areas’’ of decision-
making and address current gaps in the evidence base; in
particular, those patient factors (e.g. moderate and
severe dementia) which resulted in significant
International Journal of Stroke, 0(0)
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heterogeneity in decision-making among participants in
the current study. Future research could apply this
method to make between-country comparisons of IV
alteplase decision-making and should investigate add-
itional factors beyond those included in this study.
National stroke audit programs should consider includ-
ing additional patient variables, such as pre-stroke cog-
nitive status, in data collection strategies, as this could
further illuminate variances in decision-making about
the offer of IV alteplase.
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